Disitamab Vedotin
Antibody–drug conjugate
Also known as PF-08046051
Evidence outlook
Approved: With toripalimab, first-line HER2-expressing (IHC 1+/2+/3+) locally advanced or... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the USGastric Cancer · Phase 3 · investigational in the USHER2-Positive Breast Cancer · Phase 2/3 · investigational in the USUrothelial Carcinoma · Phase 3 · investigational in the US
Also approved (5)
- With toripalimab, first-line HER2-expressing (IHC 1+/2+/3+) locally advanced or metastatic urothelial cancer
- HER2-low (IHC 1+ or IHC 2+/ISH-) unresectable or metastatic breast cancer with liver metastases after at least one systemic therapy. Label does not mention hormone receptor status, so not mapped to the HR+/HER2- market.
- HER2-positive advanced breast cancer with liver metastases after trastuzumab (or biosimilar) and a taxane
- Conditional approval: HER2-expressing urothelial cancer, second-line and later
- Conditional approval: HER2-expressing third-line and later gastric cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04400695 NCT04400695 · Breast Cancer This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry. Registry: NCT04400695 | 3 | Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee (within approximately 3 years) 2027-12-31 | In progress: results expected 31 Dec 2027 | Partial signal | link ↗ |
View 1 more trial
NCT03052634 NCT03052634 · Advanced Breast Cancer The study was non-randomized, open-label, and had no comparator arm; all participants received disitamab vedotin at one of several doses. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT03052634 | 1/2 | RP2D (Estimated 2 year) 2022-07-31 | Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (96)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Trastuzumab brengitecan and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for HER2-Positive Breast Cancer: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Disitamab Vedotin: this drug | Phase 2/3 | Antibody–drug conjugate | HER2 | Partial signal | NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). | |
| Margetuximab (Margenza) | Approved | Monoclonal antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Neratinib | Approved | Small molecule | EGFR/HER2 | Reliable signal | NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events | |
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Pertuzumab | Approved | Monoclonal antibody | HER2/neu Receptor Antagonist | Reliable signal | NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016). NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results). | |
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | Partial signal | NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) | |
| Trastuzumab Emtansine | Approved | Antibody–drug conjugate | HER2 (ERBB2) | Partial signal | Featured results are non-efficacy only in this race | |
| Tucatinib | Approved | Small molecule | HER2 | Reliable signal | NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1) | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (HB1801) | Phase 3 | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Pyrotinib | Phase 3 | Small molecule | EGFR/HER1, HER2, HER4 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Pamirtecan | Phase 3 | Antibody–drug conjugate | HER2 | Partial signal | NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Phase 3 | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Bizrolertinib | Phase 2/3 | Small molecule | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Evorpacept | Phase 2 | Protein / enzyme therapeutic | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1(overall) | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(59 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Disitamab Vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (8)
December 2026 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (27)
January 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (4)
What to watch
What to watch
What to watch
What to watch
June 2027 (2)
August 2027 (2)
September 2027 (2)
October 2027 (2)
December 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (14)
January 2028 (1)
What to watch
March 2028 (2)
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (3)
What to watch
What to watch
What to watch
June 2028 (2)
July 2028 (2)
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (6)
March 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
June 2030 (1)
What to watch
2031 (3)
March 2031 (1)
What to watch
June 2031 (1)
What to watch
December 2031 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent